Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous native ESR1-pulsed DC1 vaccine alternating with autologous mutated ESR1-pulsed DC1 vaccine

A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DC1s) pulsed with either native or mutated estrogen receptor alpha (ERa; estrogen receptor 1; ESR1), with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated to produce DC1s and pulsed with either native or mutated ESR1. Alternating weekly between autologous native ESR1-pulsed and mutated ESR1-pulsed DC1 vaccine, upon administration, the autologous native and/or mutated ESR1-pulsed DC1 vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against ESR1-positive tumor cells, which may result in tumor cell death and decreased tumor growth. ESR1 is overexpressed and/or mutated in certain cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous DC1s pulsed with native or mutated ESR1
autologous native ESR1-pulsed DC1s/mutated ESR1-pulsed DC1s
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search